Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin after 14 Days as Add-on to Insulin in Adult Patients with

  Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin after 14
  Days as Add-on to Insulin in Adult Patients with Type 1 Diabetes Presented
  at the 2013 American Diabetes Association Scientific Sessions®

  *Mean daily blood glucose measured by continuous glucose monitoring (CGM)
    decreased with dapagliflozin on day seven; mean 7-point blood glucose
    trended downward in all treatment groups through day seven
  *Reductions in total daily insulin dosing at day seven were observed with
    dapagliflozin
  *Hypoglycemia was common in all groups and occurred more frequently with
    dapagliflozin

Business Wire

CHICAGO -- June 22, 2013

AstraZeneca(NYSE: AZN) and Bristol-Myers Squibb Company(NYSE: BMY) today
announced results from a two-week Phase IIa pilot study evaluating
dapagliflozin added to insulin in 70 adult patients with sub-optimally
controlled type 1 diabetes. Results from this study showed that in patients
treated with dapagliflozin, no subjects discontinued due to lack of glycemic
control, few genital and urinary tract infections were reported and
hypoglycemia was observed in all treatment groups. In addition, mean daily
blood glucose derived from 7-point glucose measurements trended downward in
all treatment groups through day seven and reductions in total daily insulin
dosing at day seven were observed with dapagliflozin. These findings will be
presented Sunday, June 23, in a late-breaking poster session at the 73^rd
Scientific Sessions^® of the American Diabetes Association in Chicago.

In this study, there was one case of major hypoglycemia in the dapagliflozin
10 mg group that led to discontinuation. The proportion of adverse events
(excluding hypoglycemia events) was 61.5% for the placebo group and 38.5%,
46.7%, 50.0% and 40.0% for the dapagliflozin 1, 2.5, 5 and 10 mg groups added
on to background insulin, respectively. The proportion of hypoglycemia events
was 61.5% for the placebo group and 92.3%, 60.0%, 78.6% and 66.7% for the
dapagliflozin 1, 2.5, 5 and 10 mg groups added on to background insulin,
respectively. There were two cases of urinary tract infection reported (one in
the placebo group and one in the dapagliflozin 2.5 mg group) and two cases of
genital infections (one in the dapagliflozin 1 mg group and one in the
dapagliflozin 5 mg group). One serious adverse event was reported
(gastroparesis) in the dapagliflozin 5 mg group, which was not considered
treatment-related, and was the only adverse event that led to discontinuation.

“Many people with type 1 diabetes may benefit from other treatment options in
addition to insulin,” said Robert Henry, M.D., director, Center for Metabolic
Research VA San Diego Healthcare System and primary study investigator. “These
preliminary data with dapagliflozin added on to insulin are encouraging and
support the need for further studies.”

Results of the study’s exploratory objectives showed a dose-dependent increase
in urine glucose excretion with dapagliflozin at day seven based on mean
change from baseline (41.9, 48.5, 72.4 and 88.8 grams/24 hours for the 1, 2.5,
5 and 10 mg doses, respectively) compared with a decrease for placebo (-21.6
grams). Continuous glucose monitoring (CGM) data suggested a dose-dependent
potential for reduced glycemic levels based on mean change from baseline in
average daily glucose (-15.7, -13.9, -29.5 and -41.3 mg/dL for the 1, 2.5, 5
and 10 mg doses, respectively; -20.4 mg/dL for placebo). In addition,
reductions in total daily insulin dosing at day seven were reported for the
higher dapagliflozin doses (-19.31% for 5 mg and -16.17% for 10 mg compared to
1.66% for placebo). The investigator notes that the small population size
limits the ability to interpret the data from this study.

Dapagliflozin, an investigational oral compound, is a selective and reversible
inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently
of insulin. Dapagliflozin is currently approved for the treatment of type 2
diabetes in the European Union, Australia, New Zealand and Mexico. In January
2012, the U.S. Food and Drug Administration (FDA) issued a complete response
letter regarding the New Drug Application (NDA) for dapagliflozin for the
treatment of adults with type 2 diabetes, requesting additional clinical data
to allow a better assessment of the benefit-risk profile for dapagliflozin.

“We are excited to have the opportunity to explore the potential of
dapagliflozin in patients with type 1 diabetes,” said Briggs Morrison,
executive vice president Global Medicines Development and Chief Medical
Officer, AstraZeneca. “The AstraZeneca/Bristol-Myers Squibb Diabetes Alliance
is dedicated to addressing the global burden of diabetes by advancing
individualized patient care and these study results, while preliminary, align
with this commitment.”

Study Design

This was a two-week randomized, double-blind, placebo-controlled, Phase IIa
pilot study which evaluated dapagliflozin added to insulin in patients with
sub-optimally controlled type 1 diabetes. Seventy adult patients on stable
insulin with HbA1c 7-10% (baseline mean 8.5%) were randomized to receive
dapagliflozin (1 mg, 2.5 mg, 5 mg or 10 mg) or placebo once daily for 14 days.
The primary objective of the study was to assess safety and tolerability of
dapagliflozin after 14 days as add-on to insulin in adult patients with type 1
diabetes. Secondary objectives included change from baseline at seven days in
7-point glucose monitoring profiles and pharmacokinetics. Exploratory
objectives included change from baseline at seven days in CGM profiles and
24-hour urine glucose output.

About SGLT2 Inhibition

The kidney plays an important role in glucose balance, normally filtering ~180
g of glucose each day from circulation into urine, with virtually all of the
filtered glucose subsequently being reabsorbed back into circulation by the
kidney. SGLT2 is a glucose transporter found in the kidney which plays a
critical role in glucose reabsorption. Selective inhibition of SGLT2 blocks
reabsorption of glucose from the urine, facilitating its removal in an
insulin-independent manner.

About Diabetes

In 2012, diabetes was estimated to affect more than 370 million people
worldwide. The prevalence of diabetes is projected to reach more than 550
million by 2030. While type 2 diabetes accounts for approximately 90% to 95%
of all cases of diagnosed diabetes in adults, ^ type 1 diabetes is more often
diagnosed in children and young adults and occurs when the body does not
produce insulin.

AstraZeneca/Bristol-Myers Squibb Diabetes Alliance

Dedicated to addressing the global burden of diabetes by advancing
individualized patient care, AstraZeneca and Bristol-Myers Squibb are working
in collaboration to research, develop and commercialize a versatile portfolio
of innovative treatment options for diabetes and related metabolic disorders
that aim to provide treatment effects beyond glucose control. Find out more
about the Alliance and our commitment to meeting the needs of health care
professionals and people with diabetes at www.astrazeneca.com or www.bms.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialization of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information about Bristol-Myers Squibb, visit
www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

AstraZeneca Cautionary Statement Regarding Forward-Looking Statements

In order, among other things, to utilize the 'safe harbor' provisions of the
US Private Securities Litigation Reform Act 1995, we are providing the
following cautionary statement: This press release contains certain
forward-looking statements with respect to the operations, performance and
financial condition of the Group. Although we believe our expectations are
based on reasonable assumptions, any forward-looking statements, by their very
nature, involve risks and uncertainties and may be influenced by factors that
could cause actual outcomes and results to be materially different from those
predicted. The forward looking statements reflect knowledge and information
available at the date of preparation of this press release and AstraZeneca
undertakes no obligation to update these forward-looking statements. We
identify the forward-looking statements by using the words 'anticipates',
'believes', 'expects', 'intends' and similar expressions in such statements.
Important factors that could cause actual results to differ materially from
those contained in forward-looking statements, certain of which are beyond our
control, include, among other things: the loss or expiration of patents,
marketing exclusivity or trademarks, or the risk of failure to obtain patent
protection; the risk of substantial adverse litigation/government
investigation claims and insufficient insurance coverage; exchange rate
fluctuations; the risk that R&D will not yield new products that achieve
commercial success; the risk that strategic alliances and acquisitions will be
unsuccessful; the impact of competition, price controls and price reductions;
taxation risks; the risk of substantial product liability claims; the impact
of any failure by third parties to supply materials or services; the risk of
failure to manage a crisis; the risk of delay to new product launches; the
difficulties of obtaining and maintaining regulatory approvals for products;
the risk of failure to observe ongoing regulatory oversight; the risk that new
products do not perform as we expect; the risk of environmental liabilities;
the risks associated with conducting business in emerging markets; the risk of
reputational damage; the risk of product counterfeiting; the risk of failure
to successfully implement planned cost reduction measures through productivity
initiatives and restructuring programs; the risk that regulatory approval
processes for biosimilars could have an adverse effect on future commercial
prospects; and the impact of increasing implementation and enforcement of more
stringent anti-bribery and anti-corruption legislation. Nothing in this press
release should be construed as a profit forecast.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995 regarding
product development. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including factors
that could delay, divert or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Among other risks, there can be
no guarantee that dapagliflozin will receive regulatory approval in the U.S.
or, if approved, that it will become commercially successful. There is also no
guarantee that the additional studies of the currently-approved product
described in this release will lead to additional approved indications for the
product. Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb's
business, particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended
December 31, 2012, in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.

Contact:

Media:
Shelly Mittendorf, Bristol-Myers Squibb, 609-480-2951,
shelly.mittendorf@bms.com
Kristin Rogers, AstraZeneca, 302-885-8922, kristin.rogers@astrazeneca.com
or
Investors:
John Elicker, Bristol-Myers Squibb, 609-252-4611, john.elicker@bms.com
Karl Hard, AstraZeneca, 44-20-7604-8123, karl.j.hard@astrazeneca.com